ArticleLe infezioni in medicina2026
Clinical characteristics of community acquired pneumonia due to
Article in Le infezioni in medicina, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Methods: This retrospective study included all patients admitted with Results: A total of 124 patients were included; 79.8% were <18 years (median age 9 years, IQR 6-14). Diagnosis was PCR-based in 97.6%. Cough (97.6%) and fever (95.2%) were the most common symptoms. Nineteen patients (15.3%) required supplemental oxygen, three (2.4%) non-invasive ventilation, and five (4.0%) invasive mechanical ventilation. Pleural effusion was noted in 24.2%. Extrapulmonary complications were rare, including one case each of encephalitis and pericardial effusion. Definitive therapy included doxycycline in 76.6%, azithromycin in 17.7%, and levofloxacin in 3.2%. One-third of patients initially started on macrolides required a change to alternative agents. Corticosteroids were used in 18.5%, and 33.0% required ICU care. Three patients (2.4%) died, all with significant comorbidities. Conclusions: During the 2024-2025 outbreak,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.